TP53 and B-cell chronic lymphocytic leukemia: With widely available novel therapies and improved survival outcomes for patients with TP53 aberrant CLL, “high-risk” may be refined dynamically by younger age with a short response to the first novel agent, and by diminished availability of sequential therapies.